Please assess the completion status of the following clinical trial:

Trial Title: Medicoeconomic Evaluation of Two Surgical Techniques for Lobectomy in the Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have given their consent~* Any patient with proven or suspected lung cancer treated by lobectomy or segmentectomy.~* Patients with a negative mediastinoscopy or negative  EBUS-EUS  following a PET scan showing uptake in mediastinal lymph nodes in the preoperative examination.~* Age ≥ 18 years~* Patient affiliated to a social security regimen~* Patients with a WHO performance status equal to 0 or 1.~Exclusion Criteria:~* Adults under wardship~* Pregnant or breast-feeding women~* Tumours in contact with the pulmonary artery or developing in the lobar bronchi after bronchial fibroscopy.~* Tumours in contact with the costal periosteum or invading the chest wall~* Tumours invading the mediastinal pleura or structures of the mediastinium (superior vena cava, trachea, the main-stem bronchi, aorta, oesophagus, vertebrae)~* Tumours invading the diaphragm~* Tumours invading the neurovascular structures of the apex (brachial plexus, subclavicular artery, subclavicular vein) causing Pancoast-Tobias syndrome~* Patients with histologically-proven contralateral or supraclavicular lymph node (N3) involvement whatever the harvesting method.~* Patients with a positive mediastinoscopy or positive EBUS-EUS following a PET scan with uptake in one or more mediastinal lymph nodes.~* Patients with metastasis (brain, bone, liver, adrenal glands, contralateral lung, pleura).~* Patients who have undergone neo-adjuvant chemotherapy and/or radiotherapy.~* Patients included in a neo-adjuvant chemotherapy and/or radiotherapy protocol.~* Patients who have already undergone thoracotomy.~* Patients with decompensated heart failure or with a systolic ejection fraction below 30%.~* Patients with severe pulmonary artery hypertension.~* Patients with untreated valve disease.~* Patients with unstable angina despite appropriate treatment.~* Patients with untreated carotid stenosis greater than 70%.~* Patients with histologically proven cirrhosis with various decompensations or who have presented haemoptysis because of oesophageal varicose veins.~* Patients with severe neurological sequellae (hemiplegia, paraplegia, tetraplegia).~* Patients presenting severe psychiatric disorders (dementia, psychosis).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lobectomy or segmentectomy using video-thoracoscopy (Type: EXPERIMENTAL): None
- Lobectomy or segmentectomy using thoracotomy (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).